108

News

FDA finally approves new promising Novo Nordisk medicine

Christian Wenande
November 22nd, 2016


This article is more than 8 years old.

Xultophy will be ready for the US market sometime in the first half of 2017

Novo year, novo product (photo: Novo Nordisk)

It took a while, but the Danish pharmaceutical giant Novo Nordisk’s new diabetes product Xultophy has finally been approved by the US Food and Drug Administration (FDA).

Xultophy, which is a combination of two of Novo Nordisk’s new products (Victoza and Tresiba), is a product for adults with type-2 diabetes.

“We are pleased with the approval of Xultophy 100/3.6 and look forward to launching it in the US in the first half of 2017,” said Mads Krogsgaard Thomsen, the executive vice president and chief science officer of Novo Nordisk.

“We believe Xultophy 100/3.6 offers significant benefits and is an important and convenient treatment option especially for people not achieving sufficient glycaemic control with basal insulin.”

READ MORE: Bernie Sanders blasts Novo Nordisk for price hikes

Delayed approval
The product, which was approved in Europe in 2014, is expected to be launched in the US during the first half of 2017.

A committee under the umbrella of the FDA decided unanimously in May 2016 that Xultophy should be approved, but the FDA decided to extend the approval process earlier this year.

Novo Nordisk will hope the new medication will boost its business in the US, which has suffered mightily recently due to pricing challenges in the US market.


Share

Most popular

Subscribe to our newsletter

Sign up to receive The Daily Post

















Latest Podcast

A survey carried out by Megafon for TV2 has found that 71 percent of parents have handed over children to daycare in spite of them being sick.

Moreover, 21 percent of those surveyed admitted to medicating their kids with paracetamol, such as Panodil, before sending them to school.

The FOLA parents’ organisation is shocked by the findings.

“I think it is absolutely crazy. It simply cannot be that a child goes to school sick and plays with lots of other children. Then we are faced with the fact that they will infect the whole institution,” said FOLA chair Signe Nielsen.

Pill pushers
At the Børnehuset daycare institution in Silkeborg a meeting was called where parents were implored not to bring their sick children to school.

At Børnehuset there are fears that parents prefer to pack their kids off with a pill without informing teachers.

“We occasionally have children who that they have had a pill for breakfast,” said headteacher Susanne Bødker. “You might think that it is a Panodil more than a vitamin pill, if it is a child who has just been sick, for example.”

Parents sick and tired
Parents, when confronted, often cite pressure at work as a reason for not being able to stay at home with their children.

Many declare that they simply cannot take another day off, as they are afraid of being fired.

Allan Randrup Thomsen, a professor of virology at KU, has heavily criticised the parents’ actions, describing the current situation as a “vicious circle”.

“It promotes the spread of viruses, and it adds momentum to a cycle where parents are pressured by high levels of sick-leave. If they then choose to send the children to daycare while they are still recovering, they keep the epidemic going in daycares, and this in turn puts a greater burden on the parents.”